Journal
ANNALS OF SURGICAL ONCOLOGY
Volume 28, Issue 6, Pages 3034-3043Publisher
SPRINGER
DOI: 10.1245/s10434-020-09219-6
Keywords
-
Funding
- Universita` degli Studi di Verona within the CRUI-CARE Agreement
Ask authors/readers for more resources
Recurrence occurs in about one-fourth of esophageal cancer cases with pathological complete response (pCR), mainly at distant level. Local recurrences are more common in esophageal squamous cell carcinoma (SCC) cases, with the main issue being systemic disease control. SCC patients with T4 stage have an increased risk of recurrence, requiring a personalized approach in terms of adjuvant treatment and follow-up.
Background Although pathological complete response (pCR) after multimodal treatment for esophageal cancer is associated to the best prognosis, recurrence may occur in 20-40% of cases. The present study investigated the recurrence pattern and predictive factors of recurrence after pCR in patients with esophageal cancer. Methods In this study, 427 patients received preoperative treatment for either esophageal squamous cell carcinoma (SCC) or adenocarcinoma at Verona University Hospital between 2000 and 2018. Of these, 145 patients (34%) achieved a pCR. Long-term prognosis, recurrence pattern, and risk factors for relapse in pCR patients were analysed. Results During a median follow-up of 52 months, 37 relapses (25.5%) occurred, mostly at distant level (n = 28). Nearly all locoregional relapses (8/9) were detected in SCC cases. The 5-year overall survival and cancer-related survival were 71.7% (95% confidence interval [CI] 62.6-78.9%) and 77.5% (95% CI 68.5-84.2%) respectively. Male sex, higher body mass index, and cT4 were significant risk factors for recurrence at univariate analysis. The multivariate analysis confirmed the role of cT4 as predictor of recurrence only in SCCs. Conclusions Esophageal cancer recurs in about one-fourth of pCR cases. A fair number of local recurrences occurs in SCCs, but the main problem is the systemic disease control. According to our analysis, SCCs patients with cT4 stage have an increased risk to recur, so they should be managed differently by a personalized approach in terms of adjuvant treatment and follow-up.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available